newsfilter
← Latest News
Business Wire·

Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call

  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) will host an investor conference call on December 10, 2026, at 11 a.m. Central Time.
  • The company plans to present data supporting its technology's ability to detect non-obstructive coronary artery disease (NOCAD) using a simple blood sample.
  • NOCAD affects a large population often missed by conventional diagnostic pathways like invasive angiograms, with a disproportionate share of patients being women.
  • The company intends to pursue FDA Breakthrough Device designation for its NOCAD detection technology to gain prioritized regulatory review.
  • Management will discuss the commencement of clinical testing in India, the company's first international market, in partnership with Dr. Lal PathLabs & Aimil.
  • Updates will be provided on commercially available tests (Epi+Gen CHD™ & PrecisionCHD™), reimbursement progress, & strategic growth initiatives.
  • The webcast is available at https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026/dec, with telephone access available via +1 800-450-7155 (U.S./Canada) or +1 857-999-9155 (international) using Conference ID 6865370#.